Bridging the Talent Gap reports on the unique value of OBIO’s Health to Business Bridge (H2BB) business internship program. This report describes how H2BB addresses the challenge of pulling top talent into Ontario’s health science industry to address the talent gap identified by 96% of Ontario’s health science company CEOs.
On October 24th, OBIO hosted Health Economics Day workshop in partnership with St. Michael’s Hospital.
The workshop took place in the auditorium at the Li Ka Shing Knowledge Institute and featured four sessions: a moderated panel discussion with four panellists, followed by three presentations by three health economics experts.
Recently, the Minister of Innovation, Science and Economic Development launched a cross country tour to introduce the nine supercluster proposals that have been shortlisted by the federal government for the Innovation Superclusters Initiative.
Grant Burns, OBIO's Public Affairs and Communications Manager, has listed the 9 proposals and provided commentary and analysis on how they relate to the health technology sector.
On October 2nd, Andrew Hutchinson, External Research & Scouting Lead for Alexion Pharmaceuticals, provided his insights on the strategic partnering process between early stage therapeutic companies and big pharma to the OBIO community.
OBIO's Dr. Klaus Fiebig, VP Strategic Programs, recently attended an insightful workshop on the upcoming regulatory changes affecting the CE mark. Obtaining the CE mark is a "mandatory hurdle" to access the $56B EU market, and the new regulatory changes present an opportunity for medical device companies.
Should these changes adjust your CE mark milestones? Read the Klaus' analysis and decide.
On July 11th, Grant Blevins of FCA Venture Partners in Nashville Tennessee, returned to OBIO via webinar to give his second workshop on digital health. Grant focused on the "Why, When, & How Much" that early stage companies should consider when raising capital.
In the latest issue of Biotechnology Focus, OBIO President and CEO Gail Garland contributed a special report.
Anchor Companies and 'Sticky Capital': A prescription for attracting bioscience investment to Ontario
Gail Garland, President and CEO of OBIO, travelled to San Diego for BIO 2017, one of the largest annual conventions in the biotechnology industry.
Enjoy this weeks blog on Finding the Right Candidate by Sean Peel, H2BB™ Business Development Manager & Ryan Ball, H2BB™ Program Associate.
On May 12th, Grant Blevins and Andrew Bouldin of FCA Venture Partners, of Nashville, Tennessee, gave a workshop on the financing landscape of the digital health industry. FCA Venture Partners provides early stage capital for innovative digital health companies focusing on B2B SaaS.
The “Tackling the Anchor Company Challenge Summit”, assembled industry, academic, government and investment leaders committed to working together to create a mandate of action for anchoring health science companies in Ontario.
In 2015, the Ontario Bioscience Innovation Organization convened a working group (‘OBIO Tax Policy Working Group’, OTPWG) of health science industry leaders and tax experts from academia and the private sector to examine Canada’s tax incentives and their effectiveness in stimulating growth in the health science industry.
Enjoy this week's blog by Sean Peel, OBIO's H2BB™ Business Development Manager.
Enjoy Part II of the RESI Recap series authored by OBIO's Klaus Fiebig, VP Strategic Programs